Lead Product(s): Undisclosed
Therapeutic Area: Immunology Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Undisclosed
Partner/Sponsor/Collaborator: Inmagene Biopharmaceuticals
Deal Size: $230.0 million Upfront Cash: Undisclosed
Deal Type: Partnership January 11, 2021
Chi-Med grants Inmagene exclusive options to four drug candidates solely for the treatment of immunological diseases. Upon exercise of the option, Inmagene will have the right to further develop, manufacture and commercialize that specific drug candidate worldwide.